Esketamine nasal spray represents the S-enantiomer of ketamine, a medication that received FDA approval in March 2019 for treatment-resistant depression in adults. Unlike traditional antidepressants that target serotonin or norepinephrine, esketamine works through a fundamentally different pathway by acting on the brain’s glutamate system. As a non-competitive antagonist of NMDA receptors, esketamine blocks these glutamate receptors, triggering increased glutamate release that activates other receptors responsible for creating new neural connections. Esketamine nasal spray

This mechanism offers something traditional medications cannot: rapid relief. Esketamine can reduce depressive symptoms within hours or days, whereas conventional antidepressants typically require weeks to show results. The fast action connects to the stimulation of mTORC1 signaling pathway, which supports synapse formation and brain-derived neurotrophic factor production. Furthermore, esketamine restores dopamine transmission, helping reduce symptoms like anhedonia, though this dopamine release may cause temporary psychotic-like effects. Esketamine nasal spray

The FDA expanded esketamine’s approval in July 2020 to include adults with major depressive disorder experiencing acute suicidal ideation or behavior. In reality, esketamine stands as the only glutamatergic neuromodulatory agent authorized to enhance the effects of SSRIs or SNRIs. Treatment follows a structured schedule, typically twice weekly during the first month, then decreasing in frequency based on response. Esketamine nasal spray

Who qualifies for esketamine therapy

Qualification for esketamine therapy starts with a diagnosis of treatment-resistant depression, defined as failure to respond to at least two different antidepressant medications at adequate doses and durations. Patients must be 18 years or older, as esketamine has not been approved for anyone under this age. For those with moderate to severe major depressive disorder, qualification requires documented inadequate response to maximum tolerated doses of two antidepressant therapies during the current episode. Esketamine nasal spray

Specific exclusions apply. Patients with aneurysmal vascular disease, arteriovenous malformation, or history of intracerebral hemorrhage cannot receive esketamine. Those with severe hepatic impairment, uncontrolled high blood pressure, or active psychosis should avoid this therapy. Pregnancy represents another contraindication, as esketamine may cause fetal harm. Individuals with history of substance abuse require careful evaluation, as esketamine is a Schedule III controlled substance with potential for misuse.

Patients experiencing acute suicidal thoughts qualify under different criteria. For MDD with suicidal ideation or behavior, esketamine can provide rapid relief in crisis situations when used alongside an oral antidepressant. Before starting, healthcare providers conduct psychiatric evaluations examining depressive symptoms, mental health history, and responses to past treatments.

Order Esketamine Nasal Spray

Esketamine is available only through a restricted program called the SPRAVATO REMS (Risk Evaluation and Mitigation Strategy) Program. Because of risks including sedation, dissociation, respiratory depression, and potential for abuse, administration must occur at certified healthcare settings. Patients cannot take esketamine on their own. You will self-administer the nasal spray under direct supervision of a healthcare provider at a certified treatment center.

The REMS program requires facilities to meet specific certification standards, and all requirements must be satisfied before treatment begins. Patients need an adult to accompany them and assist with transportation, or documented alternative safe transport arrangements. Blood pressure monitoring occurs before and after each dose, as esketamine temporarily increases blood pressure for approximately four hours. Esketamine nasal spray

Medical Conditions and History to Discuss With Your Doctor

Before starting esketamine therapy, you need to have an open conversation with your healthcare provider about your complete medical history. Certain conditions either prevent you from receiving this treatment or require careful monitoring throughout your sessions.

Heart and blood vessel conditions

Cardiovascular health plays a central role in determining your eligibility for esketamine treatment. Patients with aneurysmal vascular disease cannot receive this medication. This includes aneurysms in the brain, chest, abdominal aorta, arms, and legs. Similarly, arteriovenous malformation or history of intracerebral hemorrhage serves as absolute contraindications.

If you’ve experienced a heart attack, stroke, or had revascularization procedures within the past 12 months, esketamine therapy is not recommended. Heart failure classified as New York Heart Association Class III or IV of any cause excludes you from treatment. Patients with hemodynamically significant valvular heart disease, such as mitral regurgitation, aortic stenosis, or aortic regurgitation, should avoid esketamine.

Uncontrolled hypertension requires attention before treatment begins. For patients under 65 years, blood pressure readings above 140/90 mmHg indicate uncontrolled hypertension. For those 65 and older, readings above 150/90 mmHg signal poor control. During clinical trials, patients with uncontrolled hypertension were excluded from enrollment. Esketamine causes blood pressure increases that peak around 40 minutes after dosing and last approximately four hours. In controlled studies, approximately 2.0% to 4.9% of patients experienced markedly abnormal blood pressure elevations compared to 0.0% to 0.9% in placebo groups.

Spravato nasal spray

Blood pressure monitoring occurs before every treatment session and again 40 minutes after administration. The largest mean maximum systolic/diastolic blood pressure increases recorded were 13.3/8.7 mmHg for patients receiving esketamine compared to 6.1/4.9 mmHg for those on placebo. Elderly patients experienced higher increases of 16.0/9.5 mmHg. Fewer than 2% of patients discontinued treatment due to blood pressure-related adverse events across all studies.

Ketamine Nasal Spray Price

Moderate liver disease requires extended monitoring, as esketamine clearance slows in patients with hepatic impairment. Severe liver disease classified as Child-Pugh class C makes esketamine therapy unsuitable.

Pregnancy and breastfeeding concerns

Esketamine is not recommended during pregnancy. Animal studies revealed evidence of fetal harm, including delayed sensorimotor development, skeletal malformations, and neuronal apoptosis at doses 0.3 times the maximum recommended human dose. Women of childbearing potential must use highly effective contraception throughout treatment and for at least six weeks after the last dose.

If you become pregnant during treatment, esketamine should be discontinued immediately. You should register with the National Pregnancy Registry for Antidepressants at 1-844-405-6185.

Breastfeeding is not recommended while receiving esketamine treatment. The medication passes into breast milk. Animal studies showed evidence of neurotoxicity and neuronal cell loss during rapid brain development. Since the effects on nursing infants remain unknown, you need to decide between discontinuing breastfeeding or discontinuing esketamine.

Buy ketamine Nasal Spray

Medication interactions require careful attention when you receive esketamine therapy. Certain drugs can amplify side effects or create dangerous combinations that affect your safety during treatment sessions.

Sedatives and CNS depressants

Central nervous system depressants pose significant interaction risks with esketamine nasal spray. The combination increases sedation, with 48% to 61% of esketamine-treated patients developing sedation and 0.3% to 0.4% experiencing loss of consciousness. Benzodiazepines such as alprazolam, diazepam, clonazepam, lorazepam, and triazolam can raise your risk of severe sleepiness when taken with esketamine therapy.

Research shows benzodiazepines don’t reduce esketamine’s antidepressant effectiveness. However, sedation incidence increases with benzodiazepine use, though dissociation rates remain similar. Your doctor may advise skipping benzodiazepine doses on treatment days or exploring alternative medications. Opioids including oxycodone and hydromorphone also intensify sedation risks and may cause respiratory depression. Close monitoring becomes necessary if you take these medications alongside esketamine treatment.

Esketamine Nasal Spray For Sale

Esketamine is available exclusively through the SPRAVATO REMS program at certified healthcare facilities. The medication cannot be purchased for home use due to risks including sedation, dissociation, respiratory depression, and potential for abuse. Esketamine is classified as a Schedule III controlled substance. You must receive all doses under direct healthcare supervision with mandatory monitoring for at least two hours after each session.

Stimulants and other nasal medications

Stimulants raise blood pressure when combined with esketamine therapy. Medications like dextroamphetamine/amphetamine and methylphenidate increase your risk of elevated blood pressure as both esketamine and stimulants affect cardiovascular function. Your doctor will monitor blood pressure closely, requiring home measurements and log keeping. Symptoms warranting emergency care include severe headache, chest pain, or sudden vision changes.

Notably, nasal decongestants like oxymetazoline and corticosteroids such as mometasone furoate don’t significantly affect esketamine absorption.

Alcohol and substance use

Alcohol consumption on treatment days raises risks of excessive sedation and respiratory depression. Your doctor will recommend avoiding alcohol during esketamine therapy, particularly on dosing days. Mixing alcohol with ketamine increases dangers including memory loss, slowed breathing, coma, and death.

Patients with substance use disorder history face greater misuse risks. Clinical trials excluded individuals with moderate or severe substance use disorder within six months. Due to supervised administration protocols, real-world studies report no abuse-related adverse events.

Buy Esketamine Online

Preparing for your treatment session

Treatment day preparation starts with your eating schedule. You must avoid food for at least two hours before esketamine treatment and 30 minutes afterward. The medication can upset your stomach, so arriving on an empty stomach reduces discomfort risk. Additionally, you need to avoid alcohol for at least 24 hours before your session.

Comfortable clothing makes a difference during the two-hour monitoring period. Soft layers that allow you to relax work best. Arriving a bit early prevents feeling rushed and gives you time to settle in. Many patients bring headphones for music and an eye mask to reduce external stimulation. If you forget these items, treatment facilities typically provide them.

You can bring a trusted friend or family member. Their role is to be a calm presence rather than direct your experience. If you take nasal corticosteroid or nasal decongestant medications, use them at least one hour before esketamine administration.

How to use the nasal spray device

You will self-administer the esketamine nasal spray under direct healthcare provider supervision. Each device delivers two sprays containing a total of 28 mg of esketamine. Blow your nose gently before using the first device only.

Hold the device upright between your thumb and first two fingers without pressing the plunger. Tilt your head back slightly, then insert the device tip into your first nostril. The nose rest should touch the skin between your nostrils. Close the other nostril, then firmly press the plunger all the way up while breathing slowly through your nose. Sniff gently after spraying.

Repeat these steps for the other nostril. If you need another device, wait five minutes to allow medication absorption. If liquid drips from your nose, dab it with a tissue but do not blow your nose.

Monitoring period after treatment

Healthcare providers monitor you for at least two hours after each dose. During this observation period, staff check your blood pressure around 40 minutes post-dose and track pulse oximetry. Research shows 90% of patients were ready for discharge at 90 minutes, with an additional 2% to 7% ready at two hours.

Driving and activity restrictions

You cannot drive or operate machinery until the next day following a restful sleep. Arrange transportation home before your appointment. Esketamine causes temporary drowsiness, dissociation, and impaired coordination that make driving dangerous.

Spravato for sale

Side effects occur in most patients receiving esketamine nasal spray, though the majority are mild and resolve within hours of administration.

Common ketamine nasal spray side effects

The most frequent side effects include dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, lethargy, increased blood pressure, vomiting, and feeling drunk. Dissociation affects patients with feeling disconnected from mind and body. Nausea occurs in 32% of patients given 84 mg doses and 27% given 56 mg doses. Sedation develops in 48% to 61% of esketamine-treated patients. Vertigo, headache, and altered taste sensations also appear commonly. Most side effects happen immediately after dosing and disappear the same day.

Serious side effects requiring immediate attention

Chest pain, shortness of breath, sudden severe headache, vision changes, or seizures require immediate medical attention. Respiratory depression and rare respiratory arrest cases occurred in post-marketing experience. Trouble urinating, frequent urgent need to urinate, pain during urination, or nighttime urination indicate bladder problems. Thoughts of suicide or self-harm warrant emergency care.

Blood pressure and breathing monitoring

Blood pressure monitoring occurs before treatment and for at least two hours afterward. Healthcare providers check BP around 40 minutes post-dose when increases peak. Pulse oximetry tracks respiratory status throughout the monitoring period.

Long-term safety considerations

Cognitive functioning remained stable in one-year and three-year open-label trials. No bladder problems emerged at one year or four years. Real-world data from nearly 1.5 million administrations showed no unexpected safety concerns.

Conclusion

Esketamine nasal spray offers rapid relief for treatment-resistant depression, but it requires careful preparation and medical oversight. As you’ve seen here, the treatment involves specific qualifications, thorough health screenings, and supervised administration through certified facilities. Undoubtedly, the medication’s potential for quick symptom improvement makes it a valuable option when traditional antidepressants haven’t worked.

Before starting treatment, have an open discussion with your healthcare provider about your complete medical history, current medications, and lifestyle factors. When you follow the guidelines and work closely with your treatment team, esketamine therapy can become a safe, effective step toward managing your depression. Esketamine nasal spray